U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264998) titled 'Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea' on Nov. 24.
Brief Summary: Why is this study being done? Many patients with a type of breast cancer (called HR-positive) take a medicine called Abemaciclib. While this medicine is effective, a very common side effect is diarrhea, which can be severe enough to disrupt treatment and reduce quality of life. The reason why some patients get diarrhea and others do not is not well understood. This study aims to investigate whether the natural bacteria living in the gut (known as the gut microbiome) play a role in this side effect. Researchers w...